OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2025-12-31-accounts

Trustees’ Annual Report for the period

From 1[st] January 2025 To 31[st] December 2025

Charity name: Salivary Gland Cancer UK

Charity registration number: 1182762

Objectives and Activities

SORP reference
Summary of the purposes of
the charity as set out in its
governing document
Para 1.17 Help those affected by rare salivary gland
cancers.
Advocate for these patients and carers by
providing peer support and information
about their disease, care and treatment.
Promote and assist research into all aspects
of salivary gland cancers, including causes,
diagnosis, treatments and cures.
To educate the public and healthcare
communities in all things related to salivary
gland cancers, including raising awareness
of symptoms.
Summary of the main
activities in relation to those
purposes for the public
benefit, in particular, the
activities, projects or
services identified in the
accounts.
Para 1.17 and
1.19
•
Supporting the community via in person
and virtual meetings for patients, carers
and clinicians.
•
Providing information and increasing
awareness via leaflets, meetings, the
website, social media and fundraising
events.
•
Raising awareness of these cancers and
their
unmet
need
via
speaking,
submitting
materials
and
attending
meetings and conferences.
•
Expansion of the network to support all
salivary gland cancer types.
•
Expansion of the charity’s outputs to
provide more research and disease
specific information.
Statement confirming
whether the trustees have
had regard to the guidance
issued by the Charity
Commission on public
benefit
Para 1.18 The trustees have kept in mind the charity
Constitution and the guidance from the
Charities Commission in all of its’ activities.
The governance documents of the Charity
are regularly reviewed at Trustee meetings.

1

The charity’s “8 aims” are regularly published via our social media outlets and are the foundation for all activities and decisions within the charity. The trustees ensure the prioritisation of activities is aligned with these aims.

Additional information (optional) You may choose to include further statements where relevant about:

SORP reference
Policy on grant making Para 1.38 We invest directly in research
infrastructure. Our first grant call funded
projects mapping the pathway to diagnosis
and developing guidance to support earlier
detection.
We have supported the rollout of a UK-wide
surgical registry, which collects clinical and
patient-reported outcomes data to improve
understanding of treatment outcomes and
disease progression.
We also rolled out our very first travel grant
so our community can apply for financial
support to travel to a relevant conference or
workshop that is aligned with our strategy
as a charity. This is available to those who
do not otherwise receive funding to attend
such events e.g. medical undergraduates,
allied healthcare professionals and patient
advocates.
Policy on social investment
including program related
investment
Para 1.38
Contribution made by
volunteers
Para 1.38 We are hugely grateful for the continued
support and contribution we received from
our volunteers assisting us in specific
projects and outputs, sharing their stories
on social media channels, and ‘on the day’
physical support at both our own events
and conferences we attend.
Other

2

Achievements and Performance

SORP reference
Summary of the main
achievements of the charity,
identifying the difference the
charity’s work has made to
the circumstances of its
beneficiaries and any wider
benefits to society as a
whole.
Para 1.20 Launch of annual Salivary Gland Cancer
Day – 4th October 2025
SGC Day was launched on 4 October 2025
at Manchester Art Gallery - the first
awareness day dedicated to these cancers
in the UK.
The initiative was created to address a
major barrier to progress: the lack of public
and professional awareness surrounding
salivary gland cancers. Through
coordinated social media campaigns,
patient storytelling and community
engagement, the day brought
unprecedented visibility to SGCUK and
these rare diseases.
Patients, clinicians and supporters across
the UK and internationally participated.
Social media posts were created in 25
languages ensuring as wide a reach as
possible. The success of the inaugural
annual awareness day has established a
powerful platform for future national
awareness campaigns.
Bringing together those living with
salivary gland cancers
We continued to host bi-annual hybrid (in
person/virtual)
meetings
during
2025,
supporting attendees with travel bursaries
for patients and their carers where needed.
The hybrid structure of our events has
facilitated strong attendance from our
community
across
the
country
and
internationally. In May 2025 we hosted a
gathering in Sheffield and October 2025’s
event was in Manchester.
We
provided
regular
communications,
newsletters and updates to the network. We
continued to produce our video series,
releasing recordings of the presentations at
our hybrid meetings to ensure we reach as
many
people
as
possible.
We
also
continued to add patient stories on social
media and on our website.
We also hosted a number of ‘stop by’
sessions online where the community could

3

drop in for a chat with members of our team
about anything they wanted to discuss.
Raising awareness amongst the general
public and the clinical community
We continue to work to increase our visibility
among the clinical and patient network by
attending
and
presenting
at
various
conferences and events.
In March we attended ESMO Rare Cancers
Congress where Dr Metcalf delivered a
presentation on behalf of the UK Salivary
Gland Cancer Research Working Group
(UKSGCRWG), titled “Advancing Salivary
Gland Cancer Research: A Multidisciplinary
Approach to Addressing the Unmet Clinical
Need.”
In June, we chaired a panel discussion at
the inaugural National Patient Data Day,
hosted by use MY data, delving into the
critical question: 'Can we create a UK-wide
data environment fit for international rare
disease research?'
In July we attended IAOO2025, where we
had a stall and our CEO Dr Emma Kinloch
delivered a keynote speech on patient
voices in research. IAOO 2025 is the 10th
World
Congress
of
the
International
Academy
of
Oral
Oncology,
bringing
together over 1,000 delegates from various
disciplines involved in oral cancer care.
We attended the Swallows Head and Neck
Conference in November to ensure SGC
patient
needs
are
represented
in
discussions on the latest surgical and
radiotherapy treatments.
We
also
joined
the
Cancer
Drug
Development Forum (CDDF) workshop in
November, titled "Enabling Smarter Clinical
Trials to Optimise Patient Care."
Our Patient and Public Involvement (PPI)
work has continued to grow and develop in
2025. We are regularly called upon to input
into the design of research studies, provide
feedback on trial protocols, help researchers
develop lay summaries of their work and
bring the perspective of those with lived
experiences to discussions.

4

Many fundraising events, both large and
small, have taken place during the year,
notably our supporters’ participation in the
London and Loch Ness Marathons and The
Big Half in London.
Bringing together the patient, clinical
and research communities to help drive
forward research and improvements in
treatments
Our Research Working Group has been
very active during 2025. Consisting of
clinicians,
researchers
and
patient
advocates from all around the UK and
beyond.
The group meets twice a year in full with 4
separate workstreams meeting throughout
the year to focus on their individual topics in
line with the charity’s aims.
Our involvement on the PRONTO trial
management committee continued as it
opened for recruitment at The Christie and
UCLH, representing a significant step
forward in optimising care for Salivary Gland
Cancer. The primary focus of this study is on
patient quality of life.

Additional information (optional) You may choose to include further statements where relevant about:

Achievements against Para 1.41 objectives set Performance of fundraising Para 1.41 activities against objectives set Investment performance Para 1.41 against objectives Other

5

Financial Review

Financial Review
Review of the charity’s
financial position at the end
of the period
Para 1.21 As at 31stDecember 2025 the charity held a
cash balance of £50,077, (prior year
£68,381). The charity had an in-year deficit of
£18,304 (prior year deficit £36,451).
The charity received income of £39,609 (prior
year £37,336) from donations raised through
fund raising initiatives and personal legacies.
The charity’s accounts for the year have been
independently reviewed with no issues
raised.
Despite an in-year deficit, the charity’s
financial position remains robust. There are
substantial fundraising activities planned for
2026 and we are predicting an in-year
surplus.
Statement explaining the
policy for holding reserves
stating why they are held
Para 1.22 The cash balance is held in order to support
the overall objectives of the charity. Cash is
used to cover operating expenses, develop
the charity’s presence through marketing and
fund specific patient/clinician events. Cash
held is also the source funds for the grants we
have issued and for any other grant making
opportunities that may arise.
Amount of reserves held Para 1.22 £50,077 in cash.
Reasons for holding zero
reserves
Para 1.22 Not applicable
Details of fund materially in
deficit
Para 1.24 Not applicable
Explanation of any
uncertainties about the
charity continuing as a going
concern
Para 1.23 There are no uncertainties around the
charity’s ability to continue as a going
concern. The Board, together with the CEO,
carefully consider the on-going running costs
of the charity when assessing the funds
available for grants and other events.
Additional information (optional)
You may choose to include further statements
Additional information (optional)
You may choose to include further statements
where relevant about:
The charity’s principal
sources of funds (including
any fundraising)
Para 1.47
Investment policy and
objectives including any
social investment policy
adopted
Para 1.46
A description of the principal
risks facing the charity
Para 1.46 The Board maintains a Risk Register for
the charity. This document highlights
governance, operational, financial,
compliance and external risks and the
mitigants in place. The Board reviews the
Risk Register periodically.
Other

6

Structure, Governance and Management

Description of charity’s
trusts:
Type of governing document
(trust deed, royal charter)

Para 1.25
The charity is governed by its Constitution.
How is the charity
constituted?
(e.g unincorporated
association, CIO)
Para 1.25 The charity is a Charitable Incorporated
Organisation.
Trustee selection methods
including details of any
constitutional provisions e.g.
election to post or name of
any person or body entitled
to appoint one or more
trustees
Para 1.25 Trustees must be appointed for a term by a
resolution passed at a properly convened
meeting of the charity trustees.
When selecting trustees, the charity trustees
have regard to the skills, knowledge and
experience
needed
for
the
effective
administration of the CIO. The Board
periodically reviews a detailed skills matrix
to identify any gaps and regularly discusses
the structure and composition of the Board
to ensure its ongoing effectiveness as a
governing body.

Additional information (optional) You may choose to include further statements where relevant about:

Policies and procedures
adopted for the induction
and training of trustees
Para 1.51 All new trustees undertake an induction
process which includes receiving an
induction pack containing relevant policies,
procedures and key organisational
information, together with an individual
meeting with the CEO. Prospective trustees
are also invited to attend Board meetings
as observers prior to their formal
appointment, enabling them to gain an
understanding of the charity’s governance,
operations and responsibilities of trustees.
Ongoing training and development needs
are identified as appropriate throughout
their tenure.
The charity’s organisational
structure and any wider
network with which the
charity works
Para 1.51
Relationship with any
related parties
Para 1.51
Other

7

Reference and Administrative details

Charity name Salivary Gland Cancer UK
Other name the charity uses
Registered charity number 1182762
Charity’s principal address International House
36-38 Cornhill
City of London
London
EC3V 3NG

8

Names of the charity trustees who manage the charity

1
2
3
4
5
6
Trustee name Office (if any) Dates acted if not for whole
**year **
Name of person (or body) entitled
to appoint trustee (ifany)
Dr Robert Metcalf Trustee The Board
Shane Lisa Draper Trustee and Chief
Financial Officer
The Board
Olorunkemi Fausat
Akanke Olaiya
Treasurer **Non-Board role The Board
Jacqueline
O’Connor
Chair of Board Start date – December
2025
The Board
Sally Crowe Trustee Start date – December
2025
The Board
Barry Thomas Trustee Start date – December
2025
The Board

– Corporate trustees names of the directors at the date the report was approved

Director name

Name of trustees holding title to property belonging to the charity

Trustee name Dates acted if not for whole year

9

Funds held as custodian trustees on behalf of others

Description of the assets Not applicable held in this capacity Name and objects of the Not applicable charity on whose behalf the assets are held and how this falls within the custodian charity’s objects Details of arrangements for Not applicable safe custody and segregation of such assets from the charity’s own assets

Additional information (optional)

Names and addresses of advisers (Optional information)

Type of Name Address
adviser

Name of chief executive or names of senior staff members (Optional information)

Dr Emma Kinloch - CEO

Exemptions from disclosure

Reason for non-disclosure of key personnel details

Other optional information

10

Declarations

The trustees declare that they have approved the trustees’ report above.

Signed on behalf of the charity’s trustees

Signature(s)
Full name(s)
Position (eg Secretary,
Chair, etc)
Date
Jacqueline O’Connor Shane Lisa Draper

Chair of the Board of Trustees
Chief Financial Officer
19.10.26
19.10.26
19.10.26

11

Salivary Gland Cancer UK

Salivary Gland Cancer UK

Salivary Gland Cancer UK

No (if any)
1182762
CC16a
Receipts and payments accounts
For the period
from
Period start date
1st January 2025
To Period end date
31st December 2025
Section A Receipts and payments
A1 Receipts Unrestricted
funds
to the nearest
£
35,740
2,197
-
384
325
964
-
-
-
-
39,609
Restricted funds
to the nearest £
Endowment
funds
to the nearest £
Total funds
to the nearest £
Last year
to the nearest £
Donations via Just Giving, Easy Fundraising,
Paypal and otherplatforms
-
-
-
-
-
-
-
-
-
-
- 35,740 24,029
Donations received from
organisations/individuals
- 2,197 11,183
Grants from organisations/collaboration
agreements
- - 840
Shop income - 384 -
Other income - 325 -
Bank interest - 964 1,285
- - -
- - -
- - -
- - -
Sub total(Gross income for AR) - - 39,609 37,336

A2 Asset and investment sales, (see table).

Sub total(Gross income for AR) Sub total(Gross income for AR) Sub total(Gross income for AR) Sub total(Gross income for AR) Sub total(Gross income for AR) Sub total(Gross income for AR)
A2 Asset and investment sales,
**(see table). **
-
-
-
-
- -
- - -
Sub total
-
- - - -
Total receipts
A3 Payments
37,807
17,112
124
665
1,270
936
-
-
-

57,913
- - 39,609 37,336
Charity admin expenses and running costs -
-
-
-
-
-
-
-
-
- 37,807 33,073
In person meeting expenses e.g. room hire - 17,112 17,379
Bursaries for attendees - 124 508
Memberships and collaborative expenses - 665 316
Entry into events for members fundraising - 1,270 1,510
Grants - 936 21,000
- - -
- - -
- - -
Sub total - - 57,913 73,787

A4 Asset and investment purchases, (see table)

A4 Asset and investment
purchases, (see table)
A4 Asset and investment
purchases, (see table)
A4 Asset and investment
purchases, (see table)
A4 Asset and investment
purchases, (see table)
A4 Asset and investment
purchases, (see table)
A4 Asset and investment
purchases, (see table)
- - - -
- - - -
Sub total
-
- - - -
Total payments
Net of receipts/(payments)
A5 Transfers between funds
A6 Cash funds last year end
Cash funds this year end
- - 57,913 73,787
(18,304) - - -
18,304
-
36,451
- - - - -
68,381
50,077
- - 68,381 104,832
- - 50,077 68,381
Section B Statement of assets and liabilities at the end of the period
Categories
B1 Cash funds
Details
Bank account balance (Lloyds)
Notice account (Lloyds)
Unrestricted
funds
to nearest £
16,268
32,856
Restricted funds
to nearest £
Endowment
funds
to nearest £
-
-
-
-
953 - -
50,077 - -
OK OK OK
Unrestricted
funds
to nearest £
Fund to which asset
belongs
-
-
-
-
-
-
Restricted funds
to nearest £
Cost (optional)
-
-
-
-
-
-
Endowment
funds
to nearest £
-
-
-
-
-
-
Current value
(optional)
- -
- -
- -
- -
- -
Current value
(optional)
- -
- -
- -
- -
- -
- -
- -
- -
- -
When due (optional)
-
-
-
-
-
Date of approval
19.10.26
19.10.26

Shane Draper

CHARITY COMMISSION FOR ENGLAND AND WALES Independent examiner's report on the accounts Report to the trusteesl members of Salivary Gland Cancer UK On accounts for the year ended 31" December 2025 Charfty no (if any) 1182762 Set out on pages I report lo the trustees on my examination of the accounts ofthe above charity ('the Trust") for the year ended 31st December 2025. Responsibilities and As the charity trustees of the Trust, you are responsible for the preparation basis of report of the accounts in accordance with the requirements of the Charits'es Act 20111.the ACV'I. I report in respect of my examination of the Trust's accounls carried out under section 145 of the 2011 Act and in carying oul my examination, I have followed the applicable Directions given by the Charity Commission under section 145(5)(bl of the Act. I have Gompleted my examination. I confirm that no material matters have come to my attention (other than that disclosed below ') in conneclion with the examination which gives me cause to believe that in, any rnaterial respect= accounting records were not kept in accordan￿ with section 130 of the Act or the accounts do not accord with the accounting records Independent examinerfs statement I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in order to enable a proper understanding of the accounts to be reached. Please delete the words in the brackets if they do not apply. Signed: Date: Name: Mrs Karen Wicks Relevant professTonal qualification(sl or body (rf any): Accountant Address: On request IER October 2018

Only complete ifthe examiner needs lo highlight matters of Goncern (see CC32, Independent examination of charity accoLsnts.' directions and guidance for exarniners). Give here brief details of any items that the examlner wishes to disclose. IER October 2018